Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
Romain Banchereau, Avantika S. Chitre, Alexis Scherl et al. · Journal for ImmunoTherapy of Cancer · 2021
Background CD8+ tissue-resident memory T (T RM ) cells, marked by CD103 ( ITGAE ) expression, are thought to actively suppress cancer progression, leading to the hypothesis that their presence in tumors may predict response to immunotherapy. Methods Here, we test this by combining high-dimensional single-cell modalities with bulk tumor transcriptomics from 1868 patients enrolled in lung and bladder cancer clinical trials of atezolizumab (anti-programmed cell death ligand 1 (PD-L1)). Results ITGAE was identified as the most significantly upregulated gene in inflamed tumors. Tumor CD103+ CD8+ T RM cells exhibited a complex phenotype defined by the expression of checkpoint regulators, cytotoxic proteins, and increased clonal expansion. Conclusions Our analyses indeed demonstrate that the presence of CD103+ CD8+ T RM cells, quantified by tracking intratumoral CD103 expression, can predict treatment outcome, suggesting that patients who respond to PD-1/PD-L1 blockade are those who exhibit an ongoing antitumor T-cell response.
Cited by 149 works. doi:10.1136/jitc-2020-002231 Open-access PDF
Authors
- Romain Banchereau
- Avantika S. Chitre
- Alexis Scherl
- Thomas D. Wu
- Namrata S. Patil
- Patricia E. de Almeida
- Edward Ernest Kadel
- Shravan Madireddi
- Amelia Au‐Yeung
- Chikara Takahashi
- Ying‐Jiun Chen
- Zora D. Modrusan
- Jacqueline McBride
- Rhea Nersesian
- Ehab A. ElGabry
- Mark D. Robida
- Jeffrey Hung
- Marcin Kowanetz
- Wei Zou
- Mark L. McCleland
References
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- The blockade of immune checkpoints in cancer immunotherapy
- Comprehensive Integration of Single-Cell Data
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Massively parallel digital transcriptional profiling of single cells
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- The Reactome pathway Knowledgebase
- Software for Computing and Annotating Genomic Ranges
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq